Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors

Next Previous
Trial Profile

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Etoricoxib (Primary) ; H56IC (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Acronyms TBCOX2

    • Most Recent Events

    • 16 Oct 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top